The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies.


Journal

Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693

Informations de publication

Date de publication:
12 2020
Historique:
received: 18 08 2019
revised: 02 07 2020
accepted: 18 08 2020
pubmed: 23 8 2020
medline: 25 11 2021
entrez: 23 8 2020
Statut: ppublish

Résumé

Deciphering the impact of metabolic intervention on response to anticancer therapy may elucidate a path toward improved clinical responses. Here, we identify amino acid-related pathways connected to the folate cycle whose activation predicts sensitivity to MYC-targeting therapies in acute myeloid leukemia (AML). We establish that folate restriction and deficiency of the rate-limiting folate cycle enzyme MTHFR, which exhibits reduced-function polymorphisms in about 10% of Caucasians, induce resistance to MYC targeting by BET and CDK7 inhibitors in cell lines, primary patient samples, and syngeneic mouse models of AML. Furthermore, this effect is abrogated by supplementation with the MTHFR enzymatic product CH

Identifiants

pubmed: 32826232
pii: 2159-8290.CD-19-0970
doi: 10.1158/2159-8290.CD-19-0970
pmc: PMC8044910
mid: NIHMS1651496
doi:

Substances chimiques

MYC protein, human 0
Proto-Oncogene Proteins c-myc 0
Folic Acid 935E97BOY8
MTHFR protein, human EC 1.5.1.20
MTHFR protein, mouse EC 1.5.1.20
Methylenetetrahydrofolate Reductase (NADPH2) EC 1.5.1.20

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1894-1911

Subventions

Organisme : NCI NIH HHS
ID : R35 CA210030
Pays : United States
Organisme : European Research Council
ID : 758848
Pays : International
Organisme : NCI NIH HHS
ID : R01 CA207083
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007171
Pays : United States
Organisme : NCI NIH HHS
ID : K08 CA222684
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

©2020 American Association for Cancer Research.

Références

Signal Transduct Target Ther. 2018 Feb 23;3:5
pubmed: 29527331
Cell. 2008 Sep 5;134(5):703-7
pubmed: 18775299
J Biol Chem. 2014 Oct 24;289(43):29642-50
pubmed: 25213861
Nat Commun. 2019 Jun 20;10(1):2723
pubmed: 31222014
Leukemia. 2007 Jul;21(7):1413-22
pubmed: 17476281
Nature. 2014 Jul 31;511(7511):616-20
pubmed: 25043025
Cell Metab. 2017 Jan 10;25(1):27-42
pubmed: 27641100
Cell. 2011 Sep 16;146(6):904-17
pubmed: 21889194
Cell Metab. 2016 Jan 12;23(1):27-47
pubmed: 26771115
Nature. 2015 Sep 24;525(7570):543-547
pubmed: 26367798
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Biochemistry. 1988 Oct 18;27(21):8014-22
pubmed: 3266075
Cancer Discov. 2013 Mar;3(3):308-23
pubmed: 23430699
Mol Cell Biol. 2002 Aug;22(16):5793-800
pubmed: 12138190
Annu Rev Cell Dev Biol. 2011;27:441-64
pubmed: 21985671
Cancer Discov. 2015 Oct;5(10):1024-39
pubmed: 26382145
Cell Chem Biol. 2017 Sep 21;24(9):1161-1180
pubmed: 28938091
Arthritis Rheum. 2006 May;54(5):1366-77
pubmed: 16645965
Nat Med. 2015 Oct;21(10):1172-81
pubmed: 26343801
Blood. 2009 Mar 26;113(13):3088-91
pubmed: 19171880
Nature. 2018 Jul;559(7715):632-636
pubmed: 29995852
N Engl J Med. 2013 May 30;368(22):2059-74
pubmed: 23634996
Nature. 2011 Aug 03;478(7370):524-8
pubmed: 21814200
Mol Nutr Food Res. 2013 Apr;57(4):661-70
pubmed: 23112124
Cell Biochem Biophys. 2004;41(3):415-34
pubmed: 15509890
Hum Mol Genet. 2001 Mar 1;10(5):433-43
pubmed: 11181567
Nature. 2010 Dec 23;468(7327):1067-73
pubmed: 20871596
Clin Cancer Res. 2015 Apr 1;21(7):1628-38
pubmed: 25623213
Nucleic Acids Res. 2013 Jul;41(13):6391-402
pubmed: 23658224
Curr Opin Clin Nutr Metab Care. 2010 Jan;13(1):24-7
pubmed: 19904199
Clin Chem. 2003 Aug;49(8):1292-6
pubmed: 12881445
Nat Med. 2017 Mar;23(3):301-313
pubmed: 28191887
Int J Tryptophan Res. 2017 Mar 15;10:1178646917691938
pubmed: 28469468
Nat Biotechnol. 2010 May;28(5):495-501
pubmed: 20436461
Cancer Discov. 2014 Dec;4(12):1406-17
pubmed: 25186948
Physiol Rev. 2013 Oct;93(4):1803-45
pubmed: 24137022
Mol Genet Metab. 1998 Jul;64(3):169-72
pubmed: 9719624
Leukemia. 2016 Jun;30(6):1375-87
pubmed: 26932576
FASEB J. 2010 Aug;24(8):2804-17
pubmed: 20305127
Blood. 2004 Apr 1;103(7):2624-9
pubmed: 14630804
BMC Geriatr. 2013 Feb 08;13:13
pubmed: 23394203
Nat Genet. 2019 Jun;51(6):990-998
pubmed: 31133746
Mol Immunol. 2010 Aug;47(14):2295-302
pubmed: 20573402

Auteurs

Angela Su (A)

INSERM UMR 944, IRSL, St Louis Hospital, University of Paris, Paris, France.

Frank Ling (F)

INSERM UMR 944, IRSL, St Louis Hospital, University of Paris, Paris, France.

Camille Vaganay (C)

INSERM UMR 944, IRSL, St Louis Hospital, University of Paris, Paris, France.

Gaetano Sodaro (G)

INSERM UMR 944, IRSL, St Louis Hospital, University of Paris, Paris, France.

Chaïma Benaksas (C)

INSERM UMR 944, IRSL, St Louis Hospital, University of Paris, Paris, France.

Reinaldo Dal Bello (R)

INSERM UMR 944, IRSL, St Louis Hospital, University of Paris, Paris, France.

Antoine Forget (A)

INSERM UMR 944, IRSL, St Louis Hospital, University of Paris, Paris, France.

Bryann Pardieu (B)

INSERM UMR 944, IRSL, St Louis Hospital, University of Paris, Paris, France.

Kevin H Lin (KH)

Department of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina.

Justine C Rutter (JC)

Department of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina.

Christopher F Bassil (CF)

Department of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina.

Gael Fortin (G)

INSERM UMR 944, IRSL, St Louis Hospital, University of Paris, Paris, France.

Justine Pasanisi (J)

INSERM UMR 944, IRSL, St Louis Hospital, University of Paris, Paris, France.

Iléana Antony-Debré (I)

INSERM UMR 1287, Gustave Roussy Institute, Université Paris-Saclay, Villejuif, France.

Gabriela Alexe (G)

Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
The Broad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, Massachusetts.

Jean-François Benoist (JF)

AP-HP, Biochemistry-Hormonology Department, Robert Debré Hospital, Paris, France.

Alain Pruvost (A)

Paris-Saclay University, CEA, INRAE, Département Médicaments et Technologies pour la santé, SPI, Gif-sur-Yvette, France.

Yana Pikman (Y)

Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Department of Cancer Biology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.

Jun Qi (J)

The Broad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, Massachusetts.
Department of Cancer Biology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.

Marie-Hélène Schlageter (MH)

AP-HP, Cellular Biology Department, St Louis Hospital, Paris, France.
INSERM U 1131, IRSL, St Louis Hospital, University of Paris, Paris, France.

Jean-Baptiste Micol (JB)

INSERM UMR 1287, Gustave Roussy Institute, Université Paris-Saclay, Villejuif, France.
Department of Hematology, Gustave Roussy Institute, Villejuif, France.

Giovanni Roti (G)

University of Parma, Department of Medicine and Surgery, Parma, Italy.

Thomas Cluzeau (T)

Department of Hematology, Centre Hospitalier Universitaire, Nice, France.

Hervé Dombret (H)

LTL, IRSL, St Louis Hospital, Paris, France.

Claude Preudhomme (C)

Laboratory of Hematology, CHU Lille, Lille, France.

Nina Fenouille (N)

INSERM UMR 944, IRSL, St Louis Hospital, University of Paris, Paris, France.

Lina Benajiba (L)

INSERM UMR 944, IRSL, St Louis Hospital, University of Paris, Paris, France.
AP-HP, Hematology Department, St Louis Hospital, Paris, France.

Hava M Golan (HM)

Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Kimberly Stegmaier (K)

Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
The Broad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, Massachusetts.

Camille Lobry (C)

INSERM UMR 1287, Gustave Roussy Institute, Université Paris-Saclay, Villejuif, France.

Kris C Wood (KC)

Department of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina.

Raphael Itzykson (R)

INSERM UMR 944, IRSL, St Louis Hospital, University of Paris, Paris, France. alexandre.puissant@inserm.fr raphael.itzykson@aphp.fr.

Alexandre Puissant (A)

INSERM UMR 944, IRSL, St Louis Hospital, University of Paris, Paris, France. alexandre.puissant@inserm.fr raphael.itzykson@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH